tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ONC Stock Latest News

BeOne Medicines price target raised to $390 from $383 at Morgan Stanley
The FlyBeOne Medicines price target raised to $390 from $383 at Morgan Stanley
1d ago
ONC
BeOne Medicines price target raised to $396 from $348 at Citizens JMP
PremiumThe Fly
BeOne Medicines price target raised to $396 from $348 at Citizens JMP
1d ago
ONC
BeOne Medicines Reports Strong Q3 2025 Growth
PremiumCompany Announcements
BeOne Medicines Reports Strong Q3 2025 Growth
2d ago
ONC
BeOne Medicines: Strong Market Position and Promising Growth Prospects Drive Buy Rating
PremiumRatings
BeOne Medicines: Strong Market Position and Promising Growth Prospects Drive Buy Rating
2d ago
ONC
BeiGene’s Earnings Call: Record Growth and Positive Outlook
PremiumCompany Announcements
BeiGene’s Earnings Call: Record Growth and Positive Outlook
2d ago
ONC
BeOne Medicines reports Q3 non-GAAP EPS $2.65, consensus 86c
PremiumThe FlyBeOne Medicines reports Q3 non-GAAP EPS $2.65, consensus 86c
2d ago
ONC
BeOne Medicines narrows FY25 revenue view to $5.1B-$5.3B from $5.0B-$5.3B
Premium
The Fly
BeOne Medicines narrows FY25 revenue view to $5.1B-$5.3B from $5.0B-$5.3B
2d ago
ONC
BeOne Medicines’ New Study on BG-75202: A Potential Game-Changer in Cancer Treatment?
Premium
Company Announcements
BeOne Medicines’ New Study on BG-75202: A Potential Game-Changer in Cancer Treatment?
10d ago
ONC
BeOne Medicines Advances in Oncology with Promising BG-T187 Study
PremiumCompany Announcements
BeOne Medicines Advances in Oncology with Promising BG-T187 Study
12d ago
ONC
BeOne Medicines Advances in Multiple Myeloma Treatment with Sonrotoclax Study
PremiumCompany Announcements
BeOne Medicines Advances in Multiple Myeloma Treatment with Sonrotoclax Study
12d ago
ONC
BeOne Medicines Advances CLL Treatment with Promising Phase 3 Study
PremiumCompany Announcements
BeOne Medicines Advances CLL Treatment with Promising Phase 3 Study
12d ago
ONC
BeOne Medicines Advances CLL and SLL Treatment with Promising Phase 3 Study
PremiumCompany Announcements
BeOne Medicines Advances CLL and SLL Treatment with Promising Phase 3 Study
12d ago
ONC
BeOne Medicines’ Zanubrutinib Study: A Potential Game-Changer for Waldenström Macroglobulinemia
PremiumCompany AnnouncementsBeOne Medicines’ Zanubrutinib Study: A Potential Game-Changer for Waldenström Macroglobulinemia
12d ago
ONC
BeOne Medicines Explores New Frontiers in Cancer Treatment with Tislelizumab Study
Premium
Company Announcements
BeOne Medicines Explores New Frontiers in Cancer Treatment with Tislelizumab Study
12d ago
ONC
BeOne Medicines Advances Cancer Treatment with Innovative Study on Sonrotoclax
Premium
Company Announcements
BeOne Medicines Advances Cancer Treatment with Innovative Study on Sonrotoclax
12d ago
ONC
BeOne Medicines Advances Study on BGB-16673 for B-Cell Malignancies
PremiumCompany Announcements
BeOne Medicines Advances Study on BGB-16673 for B-Cell Malignancies
12d ago
ONC
BeiGene’s Promising Study on Zanubrutinib for Lymphoma: A Potential Game Changer
PremiumCompany Announcements
BeiGene’s Promising Study on Zanubrutinib for Lymphoma: A Potential Game Changer
12d ago
ONC
BeOne Medicines Advances Phase 1 Study for Metastatic Breast Cancer Treatment
PremiumCompany Announcements
BeOne Medicines Advances Phase 1 Study for Metastatic Breast Cancer Treatment
12d ago
ONC
BeOne Medicines Advances Phase 3 Study for CLL/SLL Treatment
PremiumCompany Announcements
BeOne Medicines Advances Phase 3 Study for CLL/SLL Treatment
12d ago
ONC
BeOne Medicines Advances BGB-16673 Study in B-Cell Malignancies
PremiumCompany AnnouncementsBeOne Medicines Advances BGB-16673 Study in B-Cell Malignancies
12d ago
ONC
Amgen’s Tarlatamab Study: A Potential Game-Changer in Lung Cancer Treatment
Premium
Company Announcements
Amgen’s Tarlatamab Study: A Potential Game-Changer in Lung Cancer Treatment
12d ago
ONC
AMGN
BeOne Medicines’ Zanubrutinib Study: A Potential Game-Changer for Nephropathy Treatment
Premium
Company Announcements
BeOne Medicines’ Zanubrutinib Study: A Potential Game-Changer for Nephropathy Treatment
12d ago
ONC

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >